DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Evaluation of Oral Lipid Ingestion in Relation to Ovarian Androgen Secretion in Polycystic Ovary Syndrome (PCOS)

Information source: Indiana University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Polycystic Ovary Syndrome

Intervention: Salsalate (Drug); Salsalate (Drug)

Phase: N/A

Status: Recruiting

Sponsored by: Indiana University

Official(s) and/or principal investigator(s):
Frank González, M.D., Principal Investigator, Affiliation: Indiana University

Overall contact:
Frank González, M.D., Phone: (317) 948-7064, Email: gonzalef@iupui.edu

Summary

The purpose of this study is to determine the relationship between lipid-induced inflammation and ovarian androgen secretion in women with polycystic ovary syndrome (PCOS); and to examine the effect of salsalate and polygonum cuspidatum extract (PCE) containing resveratrol on lipid-induced inflammation, ovarian androgen secretion, body composition and ovulation in a subset of normal weight women with PCOS.

Clinical Details

Official title: Evaluation of the Ovarian Dynamic Response and the Inflammatory Response to Oral Lipid Challenge in Relation to Body Composition in Polycystic Ovary Syndrome

Study design: Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science

Primary outcome: White blood cell nuclear factor kappa B (NFkappaB) activation in response to oral lipid ingestion and ovarian androgen secretion in response to human chorionic gonadotropin (HCG) stimulation.

Secondary outcome:

White blood cell NFkappaB activation following oral lipid ingestion in response to 12 weeks of salsalate or PCE administration.

Ovarian androgen secretion following HCG administration in response to 12 weeks of salsalate or PCE administration.

Body composition status measured by DEXA in response to 12 weeks of salsalate or PCE administration.

Insulin sensitivity derived from an OGTT in response to 12 weeks of salsalate or PCE administration.

Ovulation rates documented by serum progesterone in response to 12 weeks of salsalate or PCE administration

Detailed description: The investigator hypothesizes that in women with PCOS, HCG administration will stimulate an exaggerated ovarian androgen response, dairy cream ingestion will stimulate white blood cells to generate an inflammatory response, and that there is a relationship between HCG-stimulated ovarian androgen secretion and the inflammatory response to dairy cream ingestion regardless of body fat status. Thirty (30) women with PCOS (10 normal weight with normal abdominal adiposity, 10 normal weight with increased abdominal adiposity and 10 obese) and 30 ovulatory control women (10 normal weight with normal abdominal adiposity, 10 normal weight with increased abdominal adiposity and 10 obese) will participate over a 3-year period. The investigator also hypothesizes that both salsalate and PCE administration for 12 weeks will attenuate the ovarian androgen response to HCG administration and the inflammatory response to dairy cream ingestion, reduce abdominal adiposity, increase insulin sensitivity and induce ovulation in normal weight women with PCOS. A subset of 16 women with PCOS of which 8 will receive salsalate (4 normal weight with normal abdominal adiposity and 4 normal weight with increased abdominal adiposity) and 8 will receive PCE (4 normal weight with normal abdominal adiposity and 4 normal weight with increased abdominal adiposity) will participate in this intervention over a 3-year period. This pilot project will help determine the feasibility of conducting a larger double-blind, randomized trial in women with PCOS to further test the latter hypothesis.

Eligibility

Minimum age: 18 Years. Maximum age: 40 Years. Gender(s): Female.

Criteria:

General Inclusion Criteria:

- Acceptable health based on interview, medical history, physical examination, and lab

tests

- Ability to comply with the requirements of the study

- Ability and willingness to provide signed, witnessed informed consent

Inclusion Criteria for PCOS:

- Between the ages of 18-40 years

- Body mass index between 18 and 25, or between 30 and 40

- Less than or equal to 8 periods annually

- An elevated serum androgen level or skin manifestations of androgen excess

- Normal thyroid function tests and normal prolactin level

- Exclusion of late-onset adrenal hyperplasia

Inclusion Criteria for Ovulatory Controls:

- Between the ages of 18-40 years

- Body mass index between 18 and 25, or between 30 and 40

- Normal regular monthly periods

- No clinical evidence of androgen excess

- No evidence of polycystic ovaries on ultrasound

Exclusion Criteria:

- Diabetes mellitus

- Clinically significant pulmonary, cardiac ,renal, hepatic, neurologic, psychiatric,

infectious, and malignant disease

- High blood pressure

- Current or recent (within 6 weeks prior to study entry) injection of any drugs known

or suspected to affect reproductive function including oral contraceptives, metformin, thiazolidinediones, glucocorticoids, GnRH-agonists, or anti-androgens (spironolactone, flutamide, etc)

- Documented or suspected history of use of recent (within one year) illicit drug abuse

or alcoholism

- Tobacco smoking if salsalate or PCE will be administered

- Ingestion of any investigational drugs within 4 weeks prior to study onset

- Pregnancy or lactation (less than or equal to 6 weeks postpartum)

Locations and Contacts

Frank González, M.D., Phone: (317) 948-7064, Email: gonzalef@iupui.edu

Indiana University Hospital, Indianapolis, Indiana 46202, United States; Recruiting
Frank González, M.D., Phone: 317-948-7064, Email: gonzalef@iupui.edu
Frank González, M.D., Principal Investigator
Additional Information

Indiana University Reproductive Endocrine and Inflammation Research Program

Starting date: February 2012
Last updated: March 17, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017